Clinical Report: Systemic Complement Activation Linked to Progression of Intermediate AMD
Overview
A longitudinal study identified systemic complement factors associated with the progression of intermediate age-related macular degeneration (iAMD) to advanced stages. Notably, lower levels of C3 and C5 were linked to increased risk of progression, suggesting potential biomarkers for risk stratification.
Background
Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, particularly affecting those with intermediate AMD (iAMD). Understanding the mechanisms behind the progression of iAMD to advanced forms, such as geographic atrophy (GA) and neovascular AMD (nAMD), is crucial for developing effective interventions. This study highlights the role of systemic complement activation in AMD progression, emphasizing the need for further research in this area.
Data Highlights
| Parameter | Value |
|---|---|
| Patients tracked | 325 |
| Mean age | 76 years |
| Female percentage | 65% |
| Progression to advanced AMD | 34% (110 patients) |
| Progression to GA | 20% (64 patients) |
| Progression to nAMD | 14% (46 patients) |
| Mean follow-up duration | 3.9 years |
Key Findings
- 34% of patients with iAMD progressed to advanced AMD over a mean follow-up of 3.9 years.
- Lower systemic levels of C3 and C5 were significantly associated with disease progression.
- C3a/C3 and C5a/C5 ratios were linked to progression to GA.
- No complement factor was statistically significant for association with progression to nAMD.
- Time-dependent receiver operating characteristic analysis indicated moderate to good discrimination between progressors and nonprogressors.
- Classical pathway components of the complement system may play a critical role in AMD pathogenesis.
Clinical Implications
The identification of systemic complement biomarkers may aid in risk stratification for patients with iAMD, potentially guiding early intervention strategies. Clinicians should consider the implications of complement dysregulation in AMD management and the potential for new therapeutic targets.
Conclusion
This study underscores the importance of systemic complement activation in the progression of iAMD and suggests that further exploration of these biomarkers could lead to improved patient outcomes through targeted therapies.
References
- University of Colorado School of Medicine, JAMA Ophthalmology, 2023 -- Systemic Complement Activation Linked to Progression of Intermediate AMD
- Retinal Physician, 2023 -- Glycoimmune Therapy as a Novel Treatment Approach for Geographic Atrophy
- Retinal Physician, 2025 -- Complement Inhibition Slows GA in Eyes With Wet AMD
- Retinal Physician, 2019 -- Complement Inhibitors for Treatment of Geographic Atrophy and Advanced Nonexudative AMD
- AAO Age-Related Macular Degeneration Guideline Summary - Guideline Central, 2025
- Retinal Physician — Complement Inhibition Slows GA in Eyes With Wet AMD
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration
- AAO Age-Related Macular Degeneration Guideline Summary - Guideline Central
- Dynamic Risk of Systemic Complement Activation With Time to Progression to Advanced Age-Related Macular Degeneration | Retinal Disorders | JAMA Ophthalmology | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
